Mylan Pharmaceuticals, Inc. Gets FDA Approval for New Product

Mylan Pharmaceuticals Inc. has received final approval to market tolterodine tablets, the generic version of Pharmacia and Upjohn’s Detrol, which is a treatment for overactive bladder, Canonsburg-based Mylan Inc. (NASDAQ:MYL) announced on Thursday. Tolterodine tablets in the one and two milligram tablet formulations had U.S. sales of approximately $61.5 million for the year ending Sept. 30, according to IMS Health. Mylan is immediately shipping the product.